Latest News & Updates

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive non-small cell lung cancer
September 22, 2022

Continue Reading »

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
September 22, 2022

Continue Reading »

FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement
August 30, 2022

Continue Reading »

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer
August 12, 2022

Continue Reading »

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive non-small cell lung cancer
September 22, 2022

Continue Reading »

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
September 22, 2022

Continue Reading »

FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement
August 30, 2022

Continue Reading »

FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer
August 12, 2022

Continue Reading »

Get More from FLASCO With Your Membership

The Corporate Membership Program allows FLASCO to expand our offerings to our membership. Every FLASCO meeting also provides the industry representative with opportunities to educate our members. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.

Corporate Members:

Diamond Elite

Diamond

Platinum

Gold

We're Here to Help Contact Us

Contact Us

Add your name, email & message below: